Compare OBK & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OBK | PHVS |
|---|---|---|
| Founded | 1912 | 2015 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.8B |
| IPO Year | 2018 | 2020 |
| Metric | OBK | PHVS |
|---|---|---|
| Price | $41.87 | $29.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 10 |
| Target Price | ★ $44.17 | $40.70 |
| AVG Volume (30 Days) | 129.3K | ★ 155.6K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.40 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.43 | N/A |
| Revenue Next Year | $5.79 | N/A |
| P/E Ratio | $17.29 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.80 | $11.51 |
| 52 Week High | $46.02 | $29.80 |
| Indicator | OBK | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 55.31 | 65.28 |
| Support Level | $39.62 | $24.55 |
| Resistance Level | $46.02 | $29.80 |
| Average True Range (ATR) | 0.88 | 1.34 |
| MACD | 0.16 | 0.32 |
| Stochastic Oscillator | 84.98 | 91.13 |
Origin Bancorp Inc is a financial holding company. The bank provides a broad range of financial services to businesses, municipalities, high-net-worth individuals, and retail clients. The bank principally operates in one business segment, community banking. The bank is engaged in attracting deposits from individuals and businesses and using these deposits and borrowed funds to originate commercial, residential mortgage, construction, and consumer loans. The bank generates the majority of its revenue from interest earned on loans and investments, service charges, and fees on deposit accounts.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.